ClinicalTrials.gg
RecruitingNCT04871399CoME-InUpdated Nov 14, 2022

Complete Mesocolic Excision in Comparison With Conventional Surgery for the Right Colon Cancer

An interventional study of Conventional Right hemicolectomy (Non-CME) and Right hemicolectomy with CME+CVL in Colon Cancer, sponsored by University of Turin, Italy. Recruiting at 14 sites in Italy. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-11-14.

Sponsored by University of Turin, Italy · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jul 2020, registered Apr 2021).
  • Started Jul 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
416
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 135 studies in Colonic Neoplasms with a site in Italy — 41 open to participants now, 56 under way, 8 of them phase 3. Colonic Neoplasms · Italy.

Planned enrollment
35th of 87
416 · median 222
Started
2020
with 10 others
No phase
29 of 135
8 open now
Primary completion
2027-01
later than 26 of 55 live
Registered
76th of 135
by date

Among the 135 studies in Colonic Neoplasms with a site in Italy, this one is the 35th largest by planned enrollment of the 87 interventional ones that give a count, is one of 11 that started in 2020, is one of 29 with no phase, reaches primary completion later than 26 of the 55 other live ones, and was the 76th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

41 of the 135 studies in Colonic Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 135 studies in Colonic Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

An Italian randomized controlled trial parallel-group in patients with a malignant tumor of the right or proximal transverse colon requiring right hemicolectomy.

Read the detailed description

This study aims to compare the Complete Mesocolic Excision With Central Vascular Ligation (CME+CVL) with the standard (non-CME) right hemicolectomy in patients with right or proximal transverse colon cancer stage II-IV(AJCC 8th edition) to determine the short and long term outcomes in terms of disease-free survival (DFS) as a primary endpoint, and safety, oncologic outcomes, quality of surgery and quality of life (QoL) as secondary endpoints.

Eligible patients will be randomized with a 1:1 ratio between CME + CVL vs standard non-CME right colectomy. The randomization sequence will be generated centrally by a computed algorithm and kept concealed to investigators.

The Right colectomy with CME + CVL includes the removal of the accessory lymphovascular supply at their origins by resecting the colon and mesocolon in an intact envelope of visceral peritoneum and mesenteric fascia. Despite the surgical approach and the type of procedure adopted, the operation should be strictly conducted following the general rules for colorectal oncologic resection, particularly as concerns proximal and distal margins length and lymph node retrieval.

All surgical approaches (open, laparoscopic, or robotic) will be allowed while the type of anastomosis performed and drain placement will be up to the surgeon's discretion.

Demographic, baseline, perioperative and postoperative characteristics will be analyzed as well.

The study expected to last six and a half years, of which one and a half years for recruiting 416 patients, 208 each arm, with five years of follow-up. Patients will be followed up at 1, 4, 12, 24, 36, and 60 months postoperatively.

03

Conditions studied

  • Colon Cancer

Browse trials for

Keywords

  • colon cancer
  • Right colon cancer
  • Complete mesocolic excision
  • CME
  • Right Hemicolectomy
  • Right Colectomy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ASA) grade I-III.
  • Right colon cancer (*The right-sided location of the cancer is defined as the location from the caecum up to the proximal third of the transverse colon), preoperative assessment of tumor stage T2-T4a, any N or T any N+ according to the National Comprehensive Cancer Network(NCCN) clinical practice guidelines in oncology: colon cancer version 2.2015); no distant .

Exclusion criteria

Exclusion Criteria:

  • Age > 85 years old.
  • T1, N0
  • T4b, any N
  • > 30.
  • disease (Abdominal and chest CT scan will be mandatory to exclude distant metastasis.)
  • (ASA) grade IV.
  • History of cancer in recent 5 years.
  • Need for Emergency surgery.
  • Infectious disease requiring treatment.
  • Pregnancy.
  • Use of systemic .
  • No history of familial adenomatous polyposis, ulcerative colitis or Crohn's disease.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
416 participants (estimated)

Study arms

  • Active comparator
    Conventional Right hemicolectomy (Non-CME)

    Patients will undergo conventional non-CME procedure.

    Procedure: Conventional Right hemicolectomy (Non-CME)

  • Experimental
    Right hemicolectomy with CME+CVL

    Patients will undergo Right hemicolectomy CME+CVL procedure.

    Procedure: Right hemicolectomy with CME+CVL

Interventions

  • ProcedureConventional Right hemicolectomy (Non-CME)

    Transecting the Ileocolic Vein and Artery close to the Superior Mesenteric Vessels without clearing the superior mesenteric vein (SMV) from the adipose tissue. Transecting the Right Colic Vein and Artery and superior right colic vein (when present) peripherally. Transecting the Right branches of the Middle Colic Vein (MCV) and the Middle Colic Artery (MCA) peripherally, without clearing the main trunk of the MCV and the MCA. The Right Gastroepiploic Vein and artery are never transacted.

  • ProcedureRight hemicolectomy with CME+CVL

    Separation of the visceral fascia from the parietal fascia by sharp dissection leaving intact mesocolon coverage. Transecting the supplying vessels at their origin from the main vessels, particularly: * The Ileocolic Vessels, The Right Colic Vessels,The superior right colic vein (when present), The Right branches of the Middle Colic Vein and of the Middle Colic Artery * The MCV and MCA at their origin in case of cancer of the hepatic flexure or of the proximal third of the transverse colon, as well as The Right Gastroepiploic Vessels at their origin from the gastrocolic trunk of Henle (GCTH) and the gastroduodenal artery. The SMV should be cleared from all adipose tissue all along its anterior surface until its intrapancreatic entrance.

06

What researchers measure

Primary outcomes

  1. Disease-free survival at 3 years

    The length of time after surgery without any signs or symptoms of local or distant recurrence.

    Time frame: 3 Years.

Secondary outcomes

  1. Safety-Operative time.

    Total time from incision to skin closure expressed in minutes.

    Time frame: Intraoperative

  2. Safety-Intraoperative blood loss.

    Defined by the volume drained in cm2 into aspiration systems and weight of gauzes, calculated, subtracting the weight of the dry gauzes and volume of saline solution used for irrigation.

    Time frame: Intraoperative

  3. Safety-Intraoperative blood transfusion.

    Defined as the number of red blood cells, platelets, or plasma units transfused during the intraoperative time.

    Time frame: Intraoperative

  4. Safety- Intraoperative Complications.

    Defined as any deviation from the ideal intraoperative course occurring during the operative time, Using the Classification of Intraoperative Complications(CLASSIC).

    Time frame: Intraoperative

  5. Early postoperative complications.

    Number of patients with any deviation from the normal postoperative course grading by The Clavien-Dindo classification.

    Time frame: 30 postoperative days.

  6. Late postoperative complications.

    The number of patients with any deviation from the normal postoperative course grading by The Clavien-Dindo classification.

    Time frame: From the 31st postoperative days to the end of the study.

  7. Safety- Length of stay.

    Defined as the length of an inpatient episode of care, calculated from the day of operation to the first discharge and based on the number of nights spent in the hospital.

    Time frame: 30 Days.

  8. Safety- Postoperative mortality rate.

    The all-cause death rate, within 30 days after surgery in or out of the hospital.

    Time frame: 30 Days.

  9. Overall Survival at 3 years

    Defined as the time from random assignment to the date of death due to any cause.

    Time frame: 3 Years.

  10. Overall Survival at 5 years.

    Defined as the time from random assignment to the date of death due to any cause.

    Time frame: 5 Years.

  11. Disease-free survival.

    Defined as the length of time after Surgical treatment (CME+CVL or Conventional non-CME procedure) that the patient survives without any signs or symptoms of colon cancer.

    Time frame: 5 Years.

  12. Other Oncologic outcomes.

    The number of positive, negative, and total lymph nodes harvested, Quality of surgery specimen, quality of life by EORTC specific Questionnaires

    Time frame: 30 Days.

07

Study locations

1 of 14 sites recruiting
08

References and documents

Publications

  • Bertelsen CA. Complete mesocolic excision an assessment of feasibility and outcome. Dan Med J. 2017 Feb;64(2):B5334. PubMed 28157065 ↗
  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum In: CA Cancer J Clin. 2020 Jul;70(4):313. doi: 10.3322/caac.21609. PubMed 30207593 ↗
  • Benz S, Tannapfel A, Tam Y, Grunenwald A, Vollmer S, Stricker I. Proposal of a new classification system for complete mesocolic excison in right-sided colon cancer. Tech Coloproctol. 2019 Mar;23(3):251-257. doi: 10.1007/s10151-019-01949-4. Epub 2019 Mar 5. PubMed 30838463 ↗
  • Johnson PM, Porter GA, Ricciardi R, Baxter NN. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol. 2006 Aug 1;24(22):3570-5. doi: 10.1200/JCO.2006.06.8866. PubMed 16877723 ↗
  • Galizia G, Lieto E, De Vita F, Ferraraccio F, Zamboli A, Mabilia A, Auricchio A, Castellano P, Napolitano V, Orditura M. Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers? A prospective study. Int J Colorectal Dis. 2014 Jan;29(1):89-97. doi: 10.1007/s00384-013-1766-x. Epub 2013 Aug 28. PubMed 23982425 ↗
  • West NP, Kobayashi H, Takahashi K, Perrakis A, Weber K, Hohenberger W, Sugihara K, Quirke P. Understanding optimal colonic cancer surgery: comparison of Japanese D3 resection and European complete mesocolic excision with central vascular ligation. J Clin Oncol. 2012 May 20;30(15):1763-9. doi: 10.1200/JCO.2011.38.3992. Epub 2012 Apr 2. PubMed 22473170 ↗
  • Bertelsen CA, Bols B, Ingeholm P, Jansen JE, Neuenschwander AU, Vilandt J. Can the quality of colonic surgery be improved by standardization of surgical technique with complete mesocolic excision? Colorectal Dis. 2011 Oct;13(10):1123-9. doi: 10.1111/j.1463-1318.2010.02474.x. PubMed 20969719 ↗
  • Kim NK, Kim YW, Han YD, Cho MS, Hur H, Min BS, Lee KY. Complete mesocolic excision and central vascular ligation for colon cancer: Principle, anatomy, surgical technique, and outcomes. Surg Oncol. 2016 Sep;25(3):252-62. doi: 10.1016/j.suronc.2016.05.009. Epub 2016 May 20. PubMed 27566031 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Jan 2027, 77 months after the start.

Of 382 non-industry interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 55. This study's planned 77 months is above that.

Counting every sponsor, half of 404 studies reached it within 30 months; a quarter within 16 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2021
First posted
May 4, 2021
StartActual
Jul 13, 2020
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Nov 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04871399
Collaborators
Federico II University, Agnelli Hospital, Italy, Ospedale della Misericordia, Candiolo Cancer Institute - IRCCS, Maggiore Bellaria Hospital, Bologna, Università degli Studi di Ferrara, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Ospedaliera Universitaria Policlinico "G. Martino", Ospedale Policlinico San Martino, University of Rome Tor Vergata, S. Andrea Hospital, European Institute of Oncology
Responsible party
Sponsor
First posted
May 4, 2021
Start date
Jul 13, 2020
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Nov 14, 2022

Study contacts

Mario Solej, MD
Contact
mariosolej@gmail.com
00393388624939
Hogla Aridai Resendiz Aguilar, MD
Contact
hogla.resendizagu@edu.unito.it
00393512338942
Maurizio Degiuli, Professor
principal investigator · University of Turin, Department of Oncology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion